The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Alphasights; Axiom Biotechnologies; Bayer; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Trieza Therapeutics; WebMD
Research Funding - Abbvie; Adaptimmune; Aldai Norte; Amgen; AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Fate Therapeutics; Genentech; Infinity Pharmaceuticals; Kite, a Gilead company; Kura Oncology; MedImmune; Mirati Therapeutics; Molecular Templates; National Cancer Institute; Pfizer; Seagen; Shattuck Labs; TCR2 Therapeutics; TP Therapeutics
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer
 
James Kuo
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Zucero Therapeutics
 
Adrian G. Sacher
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer; Tesaro
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Genentech/Roche; KisoJi Biotechnology; Merck; Pfizer
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Gritstone Bio; Pfizer
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
 
Yasutoshi Kuboki
Honoraria - Bayer; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Grace K. Dy
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline
Research Funding - AMGEN (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Tesaro (Inst)
 
Vikas Dembla
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Sanofi/Regeneron
Travel, Accommodations, Expenses - Sanofi/Regeneron
 
John C. Krauss
Research Funding - Abbvie (Inst); ACCRU (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Ignyta (Inst); Isofol Medical (Inst); NSABP Foundation (Inst); NSABP FOUNDATION (Inst); OncoMed (Inst); Shire (Inst); XBiotech (Inst)
 
Timothy F. Burns
Consulting or Advisory Role - Abbvie/Stemcentrx; Blueprint Medicines; Novartis; Thermo Fisher Scientific
 
June Kim
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Haby Henary
No Relationships to Disclose
 
Gataree Ngarmchamnanrith
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Bob T. Li
Consulting or Advisory Role - Guardant Health; Hengrui Therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Guardant Health (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - US62/514,661 (Inst); US62/685,057 (Inst)